Atlas Trials

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Clinical trial NCT03941262 · COMPLETED

Trial details

NCT number
NCT03941262
Sponsor
NKGen Biotech, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Refractory CancerMetastatic CancerRecurrent CancerUnresectable CarcinomaSolid Tumor, AdultAdvanced CancerAdvanced Solid Tumor
Start date
2019-07-15
Primary completion
2023-02-17
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.